JPS63287723A - ドーパミン受容体アゴニスト - Google Patents
ドーパミン受容体アゴニストInfo
- Publication number
- JPS63287723A JPS63287723A JP63109280A JP10928088A JPS63287723A JP S63287723 A JPS63287723 A JP S63287723A JP 63109280 A JP63109280 A JP 63109280A JP 10928088 A JP10928088 A JP 10928088A JP S63287723 A JPS63287723 A JP S63287723A
- Authority
- JP
- Japan
- Prior art keywords
- smoking
- day
- dopamine receptor
- treatment
- bromocriptine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title claims description 24
- 229940098778 Dopamine receptor agonist Drugs 0.000 title claims description 7
- 206010057852 Nicotine dependence Diseases 0.000 claims description 15
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000000391 smoking effect Effects 0.000 description 39
- 235000019504 cigarettes Nutrition 0.000 description 18
- 241000208125 Nicotiana Species 0.000 description 15
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 15
- 229960002802 bromocriptine Drugs 0.000 description 14
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 13
- 239000000779 smoke Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229940065155 bromocriptine 2.5 mg Drugs 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 4
- 206010043903 Tobacco abuse Diseases 0.000 description 3
- 235000019788 craving Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- 229960003587 lisuride Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229960001344 methylphenidate Drugs 0.000 description 2
- 229960004851 pergolide Drugs 0.000 description 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- -1 compound bromocriptine mesylate Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4775387A | 1987-05-07 | 1987-05-07 | |
| US047753 | 1987-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63287723A true JPS63287723A (ja) | 1988-11-24 |
Family
ID=21950776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63109280A Pending JPS63287723A (ja) | 1987-05-07 | 1988-05-06 | ドーパミン受容体アゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS63287723A (enExample) |
| KR (1) | KR880013556A (enExample) |
| AU (1) | AU622614B2 (enExample) |
| CH (1) | CH675834A5 (enExample) |
| DE (1) | DE3814521A1 (enExample) |
| DK (1) | DK245388A (enExample) |
| FR (1) | FR2614789B1 (enExample) |
| GB (1) | GB2204240B (enExample) |
| IT (1) | IT1219564B (enExample) |
| NL (1) | NL8801171A (enExample) |
| PH (1) | PH25495A (enExample) |
| SE (1) | SE8801708L (enExample) |
| ZA (1) | ZA883237B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797405A (en) * | 1987-10-26 | 1989-01-10 | Eli Lilly And Company | Stabilized pergolide compositions |
| DE19626621A1 (de) * | 1996-07-02 | 1998-01-08 | Hexal Ag | Pflaster zur transdermalen Anwendung von Pergolid |
| US6623752B1 (en) | 1996-07-02 | 2003-09-23 | Hexal Ag | Patch for transdermal application for pergolid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR861128B (en) * | 1985-05-06 | 1986-08-26 | Sandoz Ag | New use of dopamine agonists |
| DE3722383A1 (de) * | 1986-07-14 | 1988-01-28 | Sandoz Ag | Neue verwendung von bromocriptin |
-
1988
- 1988-04-29 DE DE3814521A patent/DE3814521A1/de not_active Withdrawn
- 1988-05-02 FR FR888805957A patent/FR2614789B1/fr not_active Expired - Lifetime
- 1988-05-03 IT IT47906/88A patent/IT1219564B/it active
- 1988-05-04 CH CH1664/88A patent/CH675834A5/de not_active IP Right Cessation
- 1988-05-04 NL NL8801171A patent/NL8801171A/nl not_active Application Discontinuation
- 1988-05-04 GB GB8810509A patent/GB2204240B/en not_active Expired - Lifetime
- 1988-05-05 DK DK245388A patent/DK245388A/da not_active Application Discontinuation
- 1988-05-05 AU AU15605/88A patent/AU622614B2/en not_active Expired - Fee Related
- 1988-05-05 ZA ZA883237A patent/ZA883237B/xx unknown
- 1988-05-05 SE SE8801708A patent/SE8801708L/ not_active Application Discontinuation
- 1988-05-06 JP JP63109280A patent/JPS63287723A/ja active Pending
- 1988-05-06 PH PH36895A patent/PH25495A/en unknown
- 1988-05-06 KR KR1019880005250A patent/KR880013556A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| SE8801708L (sv) | 1988-11-08 |
| FR2614789B1 (fr) | 1991-10-18 |
| SE8801708D0 (sv) | 1988-05-05 |
| ZA883237B (en) | 1990-01-31 |
| NL8801171A (nl) | 1988-12-01 |
| KR880013556A (ko) | 1988-12-21 |
| DK245388D0 (da) | 1988-05-05 |
| DK245388A (da) | 1988-11-08 |
| GB8810509D0 (en) | 1988-06-08 |
| IT1219564B (it) | 1990-05-18 |
| AU1560588A (en) | 1988-11-10 |
| GB2204240A (en) | 1988-11-09 |
| CH675834A5 (enExample) | 1990-11-15 |
| GB2204240B (en) | 1991-04-24 |
| FR2614789A1 (fr) | 1988-11-10 |
| IT8847906A0 (it) | 1988-05-03 |
| PH25495A (en) | 1991-07-24 |
| DE3814521A1 (de) | 1988-11-17 |
| AU622614B2 (en) | 1992-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rose et al. | Nicotine–mecamylamine treatment for smoking cessation: The role of pre-cessation therapy. | |
| US4935429A (en) | Method of treating psychostimulant addiction | |
| Malhotra et al. | Nicotine and periodontal tissues | |
| US5783207A (en) | Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine | |
| US20020019421A1 (en) | Compositions and therapy for substance addiction | |
| US6586478B2 (en) | Methods and compositions for improving sleep | |
| US4800204A (en) | Method of controlling tobacco use | |
| Gourlay et al. | Antismoking products | |
| HUP0201279A2 (en) | Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxydase inhibitor and their use for treating tobacco withdrawal symptoms | |
| US6166032A (en) | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use | |
| WO1995007690A1 (en) | Composition and method for treating nicotine craving in smoking cessation | |
| US6409991B1 (en) | Treatment and system for nicotine withdrawal | |
| Li Wan Po | Transdermal nicotine in smoking cessation: A meta-analysis | |
| AU782403B2 (en) | Method for reducing or eliminating smoking | |
| Rose et al. | Combined effects of nicotine and mecamylamine in attenuating smoking satisfaction. | |
| PL196334B1 (pl) | Zastosowanie agonistów receptorów GABA B i ich farmaceutycznie dopuszczalnych pochodnych w terapii abstynencji nikotynowej u uzależnionych od nikotyny pacjentów | |
| WO1990000896A1 (en) | USE OF BENZO(g)QUINOLINES IN TREATMENT OF NICOTINE ADDICTION | |
| US5414005A (en) | Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation | |
| JPS63287723A (ja) | ドーパミン受容体アゴニスト | |
| Corelli et al. | Medications for smoking cessation | |
| Suchanek Hudmon et al. | Current approaches to pharmacotherapy for smoking cessation | |
| JPH0569093B2 (enExample) | ||
| US20020168403A1 (en) | Compositions and therapy for substance addiction | |
| EP0725640A1 (en) | Use of lobeline for the treatment of nicotine withdrawal | |
| AU2001284704B2 (en) | Method for reducing or eliminating smoking |